Sonnet Biotherapeutics (NASDAQ:SONN) is a biopharmaceutical company engaged in developing innovative therapies with a focus on oncological and immunological conditions. Leveraging its proprietary Fully Human Albumin Binding (F H AB) technology, Sonnet aims to create biologic drugs with enhanced efficacy and reduced toxicity, providing new treatment options for patients suffering from severe diseases. The company is committed to advancing its pipeline through rigorous scientific research, strategic collaborations, and clinical development programs. Its objective is to address unmet medical needs by bringing forth novel therapeutics that can offer meaningful improvements in patients' lives.